Abstract
Objective. To investigate the three-year prognosis in refractory angina pectoris. Patients. Two hundred and forty three patients were screened at six European university hospitals for a gene therapy trial. In 150 patients refractory angina pectoris could be confirmed. Vital status was assessed after a mean of 33 months. Results. At baseline, mean age was 63±9 years and mean LVEF was 52±12%. In 61% there was a history of myocardial infarction and 83% had previously been revascularised. Mortality was 5.5% at one year and 13.5% at three years. New revascularisation options were found in 9.5% of the 243 screened patients at baseline coronary angiography. Additionally, in 6% of the trial patients the protocol-specified angiogram after three months revealed new significant stenosis, which was treated by percutaneous intervention. Conclusions. Annual mortality in refractory angina pectoris seems higher than in stable angina pectoris in general, but substantially lower than after myocardial infarction. The “refractoriness” of these patients should be re-evaluated regularly, as new revascularisation options often occur.

This publication has 15 references indexed in Scilit: